Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
BioNTech's experimental drug gotistobart nearly doubled overall survival in patients with squamous non-small cell lung cancer (NSCLC) who had already failed immunotherapy and chemotherapy. The Phase 3 PRESERVE-003 trial showed a clinically meaningful survival benefit compared to standard-of-care chemo — a significant development for a patient population with very few options left.
BioNTech's gotistobart nearly doubles survival in hard-to-treat lung cancer
BioNTech announced promising Phase 3 results for its drug candidate gotistobart in patients with squamous non-small cell lung cancer (NSCLC) — one of the most common and difficult-to-treat forms of the disease. The PRESERVE-003 trial focused on patients whose cancer had already progressed despite prior immunotherapy and chemotherapy, a group with very limited treatment options.
The headline finding: gotistobart nearly doubled overall survival compared to standard-of-care chemotherapy, representing a clinically meaningful improvement for this heavily pre-treated population.
Key Takeaways
Why it matters: Squamous NSCLC patients who progress after immunotherapy and chemo have extremely poor prognoses and limited salvage options. If these results hold up through regulatory review, gotistobart could become a meaningful new standard of care for this underserved patient population.
